Cosmos Health Reports Revenue And Operating Metrics; Projects $12M Annualized U.S. NOOR Collagen Sales With 75% Gross Margins, Pursues U.S. Expansion And M&A Pipeline Including $11.5M Pharmacy Network Acquisition; Holds $18M In Non-Core Assets To Support Strategic Investments; Says Maintains Strong Growth Despite Geopolitical Turmoil; Plans To Issue Updated 2025 Operational, Strategic, And Financial Guidance Following Q4, FY25 Results

Continues to deliver record revenue and improving operating metrics Significant expansion in the United States underway, with NOOR and other Sky Premium Life products expected to drive strong profitability supported by gross margins of approximately 75% NOOR Collagen alone is projected to generate more than $12 million in annualized revenue Strong growth expected ahead, driven by organic progress and M&A pipeline including a recent LOI to acquire an $11.5 million pharmacy distribution network Holds valuable non-core strategic real estate and digital assets with an estimated fair market value exceeding $18 million, providing meaningful balance sheet flexibility Evaluating potential monetization of non-core assets to support more efficient capital allocation accelerate strategic investments address the current valuation disconnect, including options such as share repurchases Recent geopolitical turmoil has had a negligible impact on the Company's operations, with record-breaking growth continuing at a strong pace To issue guidance update following the release of fourth quarter and full-year 2025 results Analyst coverage initiated by Zacks Small-Cap Research with a valuation of $4.50 per share CHICAGO, March 19, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today provided a corporate update and announced that it intends to issue updated operational, strategic, and financial guidance following the release of its fourth quarter and full-year 2025 financial results. Record Operating Momentum Cosmos Health continues to deliver record revenue and gross profit while improving operating metrics, reflecting disciplined execution across all core divisions. Management believes the Company is progressing toward sustained profitability as revenue continues to grow, scale efficiencies crystallize, and margins improve. The war in the Middle East and recent geopolitical turmoil have had a negligible impact on the Company's operations. The Company expects record-breaking growth to continue at a strong pace as it advances toward sustained profitability. Strong Growth Amid Significant U.S. Expansion & Partnerships with Leading Retailers Recent milestones include the continued global expansion of the Company's proprietary brands. Sky Premium Life is growing across Europe and beyond. Importantly, the Company has recently entered the United States market with its NOOR and other Sky Premium Life products. All NOOR Sky Premium Life products sold in the United States are manufactured locally in GMP-certified, FDA-registered, and UL-audited U.S. facilities, underscoring the Company's commitment to regulatory excellence and product integrity while mitigating tariff exposure and cross-border logistical risks. Cosmos Health anticipates strong gross margins of approximately 75% and significant cash flow generation from its Sky Premium Life U.S. operations. NOOR Collagen alone is projected to generate more than $12 million in annualized revenue, with additional growth expected as the Company introduces new products and expands its Sky Premium Life portfolio in the U.S. to meet strong consumer demand. C-Scrub is gaining commercial validation in the United Kingdom through expanded retail presence at Tesco, the UK's largest retailer, and Superdrug, the UK's second-largest beauty and health retailer. The Company's contract manufacturing division continues to expand through new long-term agreements, while its wholesale logistics operations are serving increasing volumes across a growing pharmacy network. R&D at the Forefront of Innovation Cosmos Health continues to advance its R&D pipeline, further strengthened by the recent appointment of Dr. Dimitrios Iliopoulos, a globally recognized expert in AI-driven drug discovery and clinical-stage biotechnology, to its Advisory Board. The Company expects to provide updates regarding significant progress across several R&D initiatives following the finalization of certain anticipated transactions. M&A Pipeline On March 6, 2026, Cosmos Health entered into a Letter of Intent to acquire an extensive pharmacy distribution network from an established pharmaceutical company serving the Greek market for almost 40 years. The network currently generates approximately $11.5 million in annual gross revenue and serves a broad base of pharmacy customers, supplying both pharmaceutical and para-pharmaceutical products. In addition, the Company is actively evaluating a robust pipeline of acquisition opportunities designed to expand its distribution footprint, enhance operating scale, and drive profitability. Balance Sheet Flexibility: $18 Million in Non-Core Assets In addition to its core healthcare operating segments, the Company holds valuable non-core strategic assets that provide meaningful balance sheet flexibility. Among others, the Company owns real estate assets with an estimated fair market value of approximately $15 million and has also deployed $3.1 million into digital assets under its treasury strategy.